Phase 1 trial: VIR-5500 t-cell engager - Fight Prostate Ca...

Fight Prostate Cancer

3,023 members•1,480 posts

Phase 1 trial: VIR-5500 t-cell engager

Maxone73 profile image
Maxone73
•2 Replies

The amount of t-cell engagers that are being developed is increasing more and more. Do they know something that we don't? 😱

VIR-5500 is a novel dual-masked T-cell engager targeting prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC).

In an ongoing Phase 1 trial, all 12 participants experienced reductions in PSA levels, with 58% achieving a PSA50 response (≥50% reduction).

The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities up to 1000 µg/kg and minimal low-grade cytokine release syndrome. These findings suggest that VIR-5500 may offer a promising therapeutic option for mCRPC patients.

prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
podsart profile image
podsart

link seems to go to paywall or other blocked account

Maxone73 profile image
Maxone73• in reply topodsart

My bad, fixed now!

Not what you're looking for?

You may also like...

Phase 3 ended: ECLIPSE trial of 177Lu-PSMA-I&T

A phase 3 clinical trial called ECLIPSE has shown that 177Lu-PSMA-I&T significantly extends the...
Maxone73 profile image
•

Immunotherapy-- Car-T, Dendritic Cell Vaccines, and BiTE... Why hasn't this been more effective??

Salutations FPC Forum people, So, when I was messaging with Soumen79, the question of APCEDEN and...
NPfisherman profile image
•

Great update: 67Cu-SAR-bisPSMA gets fast tracked by FDA

And it looks like it is way more reliable than 177Lu... The FDA has granted Fast Track Designation...
Maxone73 profile image
•

Phase 1 recruiting: QXL138AM, for CD138 expressing tumors

Another one I almost missed... CD138 is expressed in advanced and aggressive prostate cancers,...
Maxone73 profile image
•

Phase 2 trial will start soon: opaganib plus darolutamide for mCRPC

A phase 2 clinical trial will start to assess the combination of opaganib (ABC294640) and...
Maxone73 profile image
•